Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...
Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...
Clinical trials for exa-cel have shown promising results that it has been authorised by the FDA and MHRA for use in beta thalassemia and sickle cell disease. These successes make CRISPR technology, as ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
CRISPR technology has revolutionized genetic testing and disease detection, offering precise, rapid, and cost-effective diagnostic solutions. This gene-editing tool has been adapted for molecular ...
Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR Therapeutics and Dragonfly Therapeutics, if confirmed by the ...
A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...
The CRISPR/Cas9 technology is among the most exciting developments in biotechnology in recent years, a revolutionary technique which will allow faulty genes linked to any inherited disease to be ...
Department of Chemical and Biomolecular Engineering (BK21 Four), Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea ...
Shares of CRISPR Therapeutics CRSP have lost more than ... Casgevy was approved in late 2023/early 2024 for two indications —sickle cell disease (SCD) and transfusion-dependent beta-thalassemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback